Amsterdam Cardiovascular Sciences

Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial

Beernink, J. M., Jongs, N., Mosterd, C. M., Scholtes, R. A., Caldwell-McGee, A., Casillas, D., Driscoll, L., Greasley, P. J., Karlsson, C., Hammarstedt, A., Sridhar, V. S., Muskiet, M. H. A., Laverman, G. D., Cherney, D. Z. I., Bjornstad, P., van Raalte, D. H. & Heerspink, H. J. L., Aug 2025, In: Diabetes, Obesity and Metabolism. 27, 8, p. 4415-4426 12 p.

Research output: Contribution to journal › Article* › Academic › peer-review

Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial

van Baar, M. J. B., Muskiet, M. H. A., Scholtes, R. A., Touw, D. J., Nieuwdorp, M., Kramer, M. H. H., Joles, J. A., Cherney, D. Z. I., Bjornstad, P., Krebber, M. M. & van Raalte, D. H., Jul 2025, In: Diabetes, Obesity and Metabolism. 27, 7, p. 3943-3956 14 p.

Research output: Contribution to journal › Article* › Academic › peer-review

Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure

Lytvyn, Y., Scholtes, R. A., Boorsma, E. M., Sridhar, V. S., Kugathasan, L., Liu, H., Lovblom, L. E., Handoko, L., Mosterd, C. M., Floras, J. S., Burns, K., Osuntokun, T., Voors, A., van Raalte, D. H., Heerspink, H. J. L. & Cherney, D. Z. I., 1 Apr 2025, In: Physiological reports. 13, 7, e70275.

Research output: Contribution to journal › Article* › Academic › peer-review